Drug intelligence / Profile preview

KK-4277

Development stage: Phase 1
Lead developer: Kyowa Kirin
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KK-4277 is a monoclonal antibody drug candidate developed for the treatment of autoimmune diseases, primarily systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). It acts as an antagonist of protein tyrosine phosphatase receptor type S (PTPRS), targeting plasmacytoid dendritic cells (pDCs) to suppress the overproduction of interferon alpha (IFNα) without inducing cytotoxicity in pDCs. This mechanism aims to modulate immune system overactivation characteristic of SLE. The drug is being developed by Kyowa Kirin and has reached Phase 1 clinical trials in Japan and South Korea[1][2][3][4][7].

Other names: tutorsodene

Targets

PTPRS (Receptor-type protein tyrosine phosphatase sigma)

Beyond the preview

Go deeper on KK-4277.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KK-4277.

Explore the full profile